Abstract
The application of recombinant human granulocyte colony-stimulating factor (filgrastim) seems to be a safe, well tolerated and potentially effective therapy for active Crohn's disease. We report the case of an adolescent boy with Crohn's disease and intra-abdominal abscess associated who had a significant response to treatment with recombinant human granulocyte colony-stimulating factor after all standard treatments had failed.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Abdominal Abscess / etiology*
-
Adult
-
Anti-Bacterial Agents / therapeutic use
-
Antibodies, Monoclonal / therapeutic use
-
Azathioprine / therapeutic use
-
Cell Differentiation
-
Combined Modality Therapy
-
Crohn Disease / drug therapy*
-
Crohn Disease / immunology
-
Crohn Disease / pathology
-
Crohn Disease / surgery
-
Cytokines / biosynthesis
-
Drug Resistance
-
Filgrastim
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Immunosuppressive Agents / adverse effects
-
Immunosuppressive Agents / therapeutic use
-
Infliximab
-
Macrophages / pathology
-
Male
-
Methotrexate / adverse effects
-
Methotrexate / therapeutic use
-
Neutrophils / drug effects
-
Prednisone / adverse effects
-
Prednisone / therapeutic use
-
Recombinant Proteins
-
Tumor Necrosis Factor-alpha / biosynthesis
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Cytokines
-
Immunosuppressive Agents
-
Recombinant Proteins
-
Tumor Necrosis Factor-alpha
-
Granulocyte Colony-Stimulating Factor
-
Infliximab
-
Azathioprine
-
Filgrastim
-
Prednisone
-
Methotrexate